Elekta Unity MR-Linac Earns FDA Clearance

February 7, 2019 — The Elekta Unity magnetic resonance radiation therapy (MR/RT) system recently received 510(k) premarket notification from the U.S. Food and Drug Administration (FDA), clearing the technology for commercial sales and clinical use in the United States.

Unity enables the delivery of the radiation dose while simultaneously visualizing the tumor and surrounding healthy tissue with high-quality MR images. The system also integrates advanced tools that allow clinicians to adapt the patient’s treatment to this current anatomical information within a treatment session.

“Unity is a tremendous leap forward in our ability to tailor radiation therapy to each patient’s tumor and anatomy and to adapt treatment in real time as the tumor changes shape and position relative to organs at risk,” said Christopher Schultz, M.D., FASTRO FACR, Medical College of Wisconsin, Bernard and Miriam Peck Family Professor and Chairman of the Department of Radiation Oncology, at the Froedtert & MCW Cancer Network and chair of the Elekta MR-linac Consortium. “I believe this enabling technology will fundamentally transform how radiation therapy regimens are developed, implemented and adapted to achieve optimal outcomes for our patients. We are excited to offer Unity to our patients and are proud of our contributions to making this technology a clinical reality.”

For more information: www.elekta.com